Physician profile
Ajay Dashottar
NPI 1326059015
$574.39
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $519 · 2020: $40.89 · 2022: $14.70.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $159.69 | 2019 | |
| Lilly USA, LLC | $85.28 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $70.34 | 2019 | |
| Abbvie INC. | $64.65 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $62.88 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $35.05 | 2019 | |
| Janssen Pharmaceuticals, INC | $20.66 | 2019 | |
| Amarin Pharma, INC. | $16.73 | 2019 | |
| Abbott Laboratories | $15.94 | 2019 | |
| Antares Pharma, INC. | $15.92 | 2019 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $14.70 | 2022 | |
| Shire North American Group INC | $12.55 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ajay Dashottar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.